OptimizeRx Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 66 out of 482 in the Software & IT Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 24.33.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of OptimizeRx Corp is 8.45, ranking 83 out of 482 in the Software & IT Services industry. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 26.07M, representing a year-over-year increase of 22.33%, while its net profit experienced a year-over-year increase of 108.54%.
Key Metrics
The current valuation score of OptimizeRx Corp is 7.11, ranking 323 out of 482 in the Software & IT Services industry. Its current P/E ratio is 2520.83, which is 51.61% below the recent high of 3821.76 and 101.60% above the recent low of -40.41.
The current earnings forecast score of OptimizeRx Corp is 8.29, ranking 66 out of 482 in the Software & IT Services industry. The average price target is 24.00, with a high of 32.00 and a low of 17.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of OptimizeRx Corp is 7.07, ranking 107 out of 482 in the Software & IT Services industry. Currently, the stock price is trading between the resistance level at 13.46 and the support level at 9.03, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of OptimizeRx Corp is 7.00, ranking 143 out of 482 in the Software & IT Services industry. The latest institutional shareholding proportion is 76.14%, representing a quarter-over-quarter increase of 4.73%. The largest institutional shareholder is The Vanguard, holding a total of 1.14M shares, representing 6.10% of shares outstanding, with 22.37% increase in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Software & IT Services domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of OptimizeRx Corp is 4.19, ranking 270 out of 482 in the Software & IT Services industry. The company's beta value is 1.16. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
